MARKIBD

Alternative promoters as biomarkers in Inflammatory Bowel Disease

Coordinatore	KOBENHAVNS UNIVERSITET    more  Organization address postcode: 1017 contact info Titolo: Mr. Nome: Ivan Cognome: Kristoffersen Email: send email Telefono: 4535322810
Nazionalità Coordinatore	Denmark [DK]
Totale costo	221˙154 €
EC contributo	221˙154 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IEF
Funding Scheme	MC-IEF
Anno di inizio	0
Periodo (anno-mese-giorno)	0000-00-00   -   0000-00-00

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	KOBENHAVNS UNIVERSITET	DK	coordinator	221˙154.60

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Inflammatory Bowel Disease (IBD) affects up to 1 in 200 individuals in Europe. Current diagnosis of the two main subtypes of IBD (Crohn’s disease and ulcerative colitis) is based on endoscopy, radiology and the examination of biopsies with a high degree of uncertainty: 20% of patients are not classifiable or are rediagnosed later. The uncertainty in diagnosis extends also to medication, which is to a large degree based on trial and error. The use of molecular biomarkers could allow for an earlier and more specific diagnosis of disease type and more targeted therapy; this is the aim of my project. My hypothesis is that differences between inflamed and non-inflamed tissue and between disease subtypes may not only be due to differential gene expression but also to alternative promoter usage, which may lead to altered protein products with modified or aberrant function. I will apply genome-wide experimental and computational methods to study differential promoter usage i) in colon tissue biopsies from IBD patients and ii) in the model system Caco-2, where we can investigate the effect of inflammation and perform functional validation of the promoters found in patients. The aim of this is to identify alternative promoters as biomarkers for diagnostics. As one of very few research groups worldwide, my host group uses a novel technique, Cap Analysis of Gene Expression, to identify transcription start sites genome-wide, which will allow me to quantify promoter usage and to find alternative promoters. Through the project I will obtain expertise in the growing field of high-throughput sequencing analysis, while my background in bioinformatics and immunology will contribute to the success of the project. As a result, the project will provide biomarkers for diagnosis of disease subtype with the aim to make diagnosis of IBD easier and more precise, allowing for better treatment and thereby improving the quality of life for patients as well as reducing health care costs.'